Ocugen Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to treat eye diseases | Ambrx Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code. | ![]() Asklepios BioPharmaceutical Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein. | Precigen Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases. | |
Founding Date | Founding Date 2013 | Founding Date 2003 | Founding Date 2001 | Founding Date 1998 |
Type | Type Public | Type Public | Type Private | Type Public |
Tags | ||||
Locations | Locations Malvern, US HQ | Locations San Diego, US HQ | Locations Chapel Hill, US HQ Roslin, GB | Locations Germantown, US HQ Gent, BE Sioux Center, US |
Employees | Employees 84425% increase | Employees 70 | Employees 5172% increase | Employees 601 |
Valuation ($) | Valuation ($) 292.1 m | Valuation ($) 1.8 b | Valuation ($) N/A | Valuation ($) 246.6 m |
Financial | ||||
Revenue (est.) | Revenue (est.) $4.4m (FY, 2025) | Revenue (est.) $7.4m (FY, 2022) | Revenue (est.) N/A | Revenue (est.) $9.7m (FY, 2025) |
Net income | Net income ($67.8m) (FY, 2025) | Net income ($78m) (FY, 2022) | Net income N/A | Net income ($250.6m) (FY, 2025) |
Funding | ||||
Total funding raised | Total funding raised N/A | Total funding raised $ 347.9m | Total funding raised $ 235m | Total funding raised $ 379m |
Ambrx is a biopharmaceutical company that discovers and develops engineered precision biologics therapeutics using an expanded genetic code.
View company
Asklepios BioPharmaceutical is engaged in the development and delivery of novel protein.
View companyPrecigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases.
View company